"Compugen’s (CGEN) early-stage study is evaluating the safety, tolerability and preliminary antitumor activity of COM701 (the company’s first-in-class anti-PVRIG antibody) in combination with Bristol Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo (nivolumab) and BMS-986207."
I can see CGEN at $60-$75 per share min next year if a buyout occurs. I know a lot of heavy hitters are watching this and a working partnership with Bristol Myers Squibb, a 140 billion dollar beast is very encouraging.
Market Data 
Markets 
AI
